Aptose Biosciences (APTO) 10-K 10 Mar 20 2019 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 10, 2020	Jun. 30, 2019
Document Information [Line Items]
Entity Registrant Name	Aptose Biosciences Inc.
Entity Central Index Key	0000882361
Trading Symbol	apto
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		76,269,806
Entity Public Float			$ 143,417,295
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false
Title of 12(b) Security	Common Shares, without par value

Consolidated Statements of Fina

Consolidated Statements of Financial Position - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 79,842	$ 15,299
Investments	17,758	440
Prepaid expenses	1,025	646
Other current assets	141	101
Total current assets	98,766	16,486
Non-current assets:
Property and equipment	334	384
Right-of-use assets, operating leases	1,376
Total non-current assets	1,710	384
Total assets	100,476	16,870
Current liabilities:
Accounts payable	1,960	1,315
Accrued liabilities	3,058	1,474
Current portion of lease liability, operating leases	521
Total current liabilities	5,539	2,789
Non-current liabilities:
Lease liability, operating leases	1,011
Total liabilities	6,550	2,789
Shareholders’ equity:
Common shares, no par value, unlimited authorized shares, 76,108,031 and 38,161,808 shares issued and outstanding at December 31, 2019 and December 31, 2018	365,490	261,072
Additional paid-in capital	34,649	32,963
Accumulated other comprehensive loss	(4,298)	(4,316)
Deficit	(301,915)	(275,638)
Total shareholders’ equity	93,926	14,081
Total liabilities and shareholders’ equity	$ 100,476	$ 16,870

Consolidated Statements of Fi_2

Consolidated Statements of Financial Position (Parentheticals) - $ / shares $ / shares in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Common shares, par value (in dollars per share)	$ 0	$ 0
Common shares, authorized	Unlimited	Unlimited
Common shares, issued (in shares)	76,108,031	38,161,808
Common shares, oustanding (in shares)	76,108,031	38,161,808

Consolidated Statements of Loss

Consolidated Statements of Loss and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue
Expenses:
Research and development	16,835	18,733
General and administrative	10,022	10,374
Operating expenses	26,857	29,107
Other income (expense):
Interest income	574	283
Foreign exchange gain/(loss)	6	(44)
Total other income	580	239
Net loss	(26,277)	(28,868)
Other comprehensive loss:
Unrealized gain on securities available-for-sale	18
Total comprehensive loss	$ (26,259)	$ (28,868)
Basic and diluted loss per common share (in dollars per share)	$ (0.52)	$ (0.86)
Weighted average number of common shares outstanding used in the calculation of (in thousands) Basic and diluted loss per common share (in shares)	50,160	33,391

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands	December 2019 Public Offering [Member]Common Stock [Member]	December 2019 Public Offering [Member]Additional Paid-in Capital [Member]	December 2019 Public Offering [Member]AOCI Attributable to Parent [Member]	December 2019 Public Offering [Member]Retained Earnings [Member]	December 2019 Public Offering [Member]	June 2019 Public Offering [Member]Common Stock [Member]	June 2019 Public Offering [Member]Additional Paid-in Capital [Member]	June 2019 Public Offering [Member]AOCI Attributable to Parent [Member]	June 2019 Public Offering [Member]Retained Earnings [Member]	June 2019 Public Offering [Member]	The 2019 Share Purchase Agreement [Member]Common Stock [Member]	The 2019 Share Purchase Agreement [Member]Additional Paid-in Capital [Member]	The 2019 Share Purchase Agreement [Member]AOCI Attributable to Parent [Member]	The 2019 Share Purchase Agreement [Member]Retained Earnings [Member]	The 2019 Share Purchase Agreement [Member]	The 2018 ATM Offering [Member]Common Stock [Member]	The 2018 ATM Offering [Member]Additional Paid-in Capital [Member]	The 2018 ATM Offering [Member]AOCI Attributable to Parent [Member]	The 2018 ATM Offering [Member]Retained Earnings [Member]	The 2018 ATM Offering [Member]	The 2018 Purchase Agreement [Member]Common Stock [Member]	The 2018 Purchase Agreement [Member]Additional Paid-in Capital [Member]	The 2018 Purchase Agreement [Member]AOCI Attributable to Parent [Member]	The 2018 Purchase Agreement [Member]Retained Earnings [Member]	The 2018 Purchase Agreement [Member]	The 2017 Purchase Agreement [Member]Common Stock [Member]	The 2017 Purchase Agreement [Member]Additional Paid-in Capital [Member]	The 2017 Purchase Agreement [Member]AOCI Attributable to Parent [Member]	The 2017 Purchase Agreement [Member]Retained Earnings [Member]	The 2017 Purchase Agreement [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017																															27,502,000
Balance at Dec. 31, 2017																															$ 231,923	$ 29,365	$ (4,316)	$ (246,770)	$ 10,202
Common shares issued (in shares)																4,086,000				4,085,615	1,078,000					5,232,000				5,231,953
Common shares issued																$ 10,710				$ 10,710	$ 2,526				$ 2,526	$ 14,995				$ 14,995
Common shares issued upon exercise of stock options (in shares)																															114,000				114,000
Common shares issued upon exercise of stock options																															$ 415	(175)			$ 240
Common shares issued on redemption of restricted share units (in shares)																															150,000
Common shares issued on redemption of restricted share units																															$ 503	(503)
Stock-based compensation																																4,276			4,276
Net loss																																		(28,868)	(28,868)
Balance (in shares) at Dec. 31, 2018																															38,162,000
Balance at Dec. 31, 2018																															$ 261,072	32,963	(4,316)	(275,638)	$ 14,081
Common shares issued (in shares)	18,544,000					11,500,000					1,971,000					77,000					5,502,000														30,043,750
Common shares issued	$ 68,588				$ 68,588	$ 19,594				$ 19,594	$ 4,730				$ 4,730	$ 178				$ 178	$ 10,000				$ 10,000
Common shares issued upon exercise of stock options (in shares)																															312,000				312,000
Common shares issued upon exercise of stock options																															$ 1,248	(530)			$ 718
Common shares issued on redemption of restricted share units (in shares)																															40,000
Common shares issued on redemption of restricted share units																															$ 80	(80)
Stock-based compensation																																2,296			2,296
Other comprehensive gain (loss)																																	18		18
Net loss																																		(26,277)	(26,277)
Balance (in shares) at Dec. 31, 2019																															76,108,000
Balance at Dec. 31, 2019																															$ 365,490	$ 34,649	$ (4,298)	$ (301,915)	$ 93,926

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net loss for the year	$ (26,277,000)	$ (28,868,000)
Items not involving cash:
Stock-based compensation	2,296,000	4,276,000
Shares issued to Aspire Capital as commitment fees	360,000	600,000
Depreciation and amortization	152,000	87,000
Amortization of right-of-use assets	461,000
Interest on lease liabilities	90,000
Unrealized foreign exchange gain/(loss)	(23,000)	25,000
Accrued interest on investments	(34,000)
Change in operating working capital:
Prepaid expenses	(379,000)	(324,000)
Operating lease payments	(471,000)
Other assets	(40,000)	(27,000)
Accounts payable	645,000	726,000
Accrued liabilities	1,662,000	298,000
Cash used in operating activities	(21,558,000)	(23,207,000)
Cash flows from financing activities:
Offering costs paid	(437,000)	(15,000)
Issuance of common shares pursuant to exercise of stock options	718,000	240,000
Cash provided by financing activities	103,448,000	27,871,000
Cash flows from (used in) investing activities:
Maturity (acquisition) of investments, net	(17,268,000)	341,000
Purchase of property and equipment	(102,000)	(329,000)
Cash provided by (used in) investing activities	(17,370,000)	12,000
Effect of exchange rate fluctuations on cash and cash equivalents held	23,000	(8,000)
Increase in cash and cash equivalents	64,543,000	4,668,000
Cash and cash equivalents, beginning of year	15,299,000	10,631,000
Cash and cash equivalents, end of year	79,842,000	15,299,000
December 2019 Public Offering [Member]
Cash flows from financing activities:
Issuance of common shares	68,883,000
June 2019 Public Offering [Member]
Cash flows from financing activities:
Issuance of common shares	19,736,000
The 2018 ATM Offering [Member]
Cash flows from financing activities:
Issuance of common shares	178,000	10,720,000
The 2019 Share Purchase Agreement [Member]
Cash flows from financing activities:
Issuance of common shares	4,370,000
The 2018 Purchase Agreement [Member]
Cash flows from financing activities:
Issuance of common shares	10,000,000	1,926,000
The 2017 Purchase Agreement [Member]
Cash flows from financing activities:
Issuance of common shares		$ 15,000,000

Note 1 - Reporting Entity

Note 1 - Reporting Entity	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Reporting entity: Aptose Biosciences Inc. (“Aptose” or the “Company”) is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company’s executive office is located in San Diego, California and its corporate office is located in Toronto, Canada. Aptose has two third CG026806 806” 3 FLT3 1a/b, 806 1 253, second 1b Since our inception, we have financed our operations and technology acquisitions primarily from equity financing, proceeds from the exercise of warrants and stock options, and interest income on funds held for future investment. Our uses of cash for operating activities have primarily consisted of salaries and wages for our employees, facility and facility-related costs for our offices and laboratories, fees paid in connection with preclinical and clinical studies, drug manufacturing costs, laboratory supplies and materials, and professional fees. During the year ended December 31, 2019, two 30,043,750 $95.45 $88.18 two 7,302,433 $14.4 We do not We believe that our cash, cash equivalents and investments on hand at December 31, 2019 12 may We expect that we will need to raise additional capital or incur indebtedness to continue to fund our operations in the future. Our ability to raise additional funds could be affected by adverse market conditions, the status of our product pipeline and various other factors and we may not may

Note 2 - Significant Accounting

Note 2 - Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Significant accounting policies (a) Basis of consolidation: These consolidated financial statements include the accounts of its subsidiaries. All intercompany transactions, balances, revenue and expenses are eliminated on consolidation. (b) Basis of presentation: These consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States, or GAAP and the rules and regulations of the Securities and Exchange Commission, or SEC, related to annual reports filed on Form 10 (c) Significant accounting policies, estimates and judgments: The preparation of the consolidated financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of revenue and expenses during the reporting period. Actual outcomes could differ from those estimates. The consolidated financial statements include estimates, which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements and may The estimates and underlying assumptions are reviewed on a regular basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected. (d) Leases Effective January 1, 2019, No. 2016 02, 842 twelve Impact of adoption: As a result of adopting Topic 842, January 1, 2019, $1.570 $1.647 $78 (e) Cash and cash equivalents: Cash and cash equivalents are short-term highly liquid investments with original maturities of 90 (f) Investments: Investments consist of time deposits with original maturities greater than 90 (g) Concentration of risk: The Company is subject to credit risk from the Company’s cash and cash equivalents and investments. The carrying amount of the financial assets represents the maximum credit exposure. The Company manages credit risk associated with its cash and cash equivalents and investments by maintaining minimum standards of R1 (h) Property and equipment: Property and equipment is measured at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset. The Company records depreciation at rates that charge operations with the cost of the assets over their estimated useful lives on a straight-line basis as follows: Office furniture (years) 5 Laboratory equipment (years) 5 Computer hardware (years) 3 Computer software (years) 3 Leasehold improvements Life of lease The residual value, useful life and methods of depreciation of the assets are reviewed at each reporting period and adjusted prospectively if appropriate. (i) Research and development: Research and development (R&D) costs are expensed as incurred. R&D costs consist primarily of salaries and benefits, stock-based compensation, manufacturing, contract services, clinical trials, intangibles, and research related overhead. Non-refundable advance payments for goods and services that will be used in future research are recorded in prepaid and other assets and are expensed when the services are performed. (j) Fair value: The Company measures its financial assets and liabilities at fair value. The carrying amounts for the Company’s financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. (k) Stock-based compensation: The Company has a stock-based compensation plan (the “Plan”) available to officers, directors, employees and consultants with grants under the Plan approved by the Company’s Board of Directors. Under the Plan, the exercise price of each option equals the closing trading price of the Company’s stock on the day prior to the grant if the grant is made during the trading day or the closing trading price on the day of grant if the grant is issued after markets have closed. Vesting is provided for at the discretion of the Board of Directors and the expiration of options is to be no 10 The Company uses the fair value based method of accounting for employee awards granted under the Plan. The Company calculates the fair value of each stock option grant using the Black-Scholes option pricing model at the grant date. The stock-based compensation cost of the options is recognized as stock-based compensation expense over the relevant vesting period of the stock options using an estimate of the number of options that will eventually vest. Stock options awarded to non-employees are accounted for at the fair value of the goods received or the services rendered. The fair value is measured at the grant date. In June 2018, No 2018 07, 718 December 15, 2018. not The Company has a stock incentive plan pursuant to which the Board may (l) Segment reporting: Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, or CODM. The Company’s Chief Executive Officer serves as its CODM. The Company views its operations and manages its business as one (m) Loss per share: Basic loss per share is computed by dividing the net loss available to common shareholders by the weighted average number of shares outstanding during the year. Diluted loss per share is computed similarly to basic loss per share except that the weighted average share outstanding is increased to include additional shares for the assumed exercise of stock options and warrants, if dilutive. The number of additional shares is calculated by assuming that outstanding stock options and warrants were exercised and that the proceeds from such exercises were used to acquire common stock at the average market price during the year. The inclusion of the Company’s stock options and warrants in the computation of diluted loss per share has an anti-dilutive effect on the loss per share and, therefore, they have been excluded from the calculation of diluted loss per share. (n) Income taxes: The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which these temporary differences are expected to be recovered or settled. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not not The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. Reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filing is more likely than not December 31, 2019 December 31, 2018, not not

Note 3 - Cash and Cash Equivale

Note 3 - Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Cash and Cash Equivalents Disclosure [Text Block]	3. Cash and cash equivalents: Cash and cash equivalents consists of cash of $1.640 December 31, 2018 $621 90 $78.202 December 31, 2018 $14.678

Note 4 - Property and Equipment

Note 4 - Property and Equipment	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	4. Property and equipment: December 31, 2019 Cost Accumulated Net book value Laboratory equipment $ 185 $ 160 $ 25 Computer hardware 122 60 62 Computer software 222 128 94 Office furniture 116 51 65 Leasehold improvements 177 89 88 $ 822 $ 488 $ 334 December 31, 2018 Cost Accumulated Net book value Laboratory equipment $ 176 $ 129 $ 47 Computer hardware 80 40 40 Computer software 222 80 142 Office furniture 82 28 54 Leasehold improvements 160 59 101 $ 720 $ 336 $ 384

Note 5 - Right of-use Assets, O

Note 5 - Right of-use Assets, Operating Leases	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Right-of-use Assets Disclosure [Text Block]	5. Right of-use assets, operating leases: Year ended Year ended Right-of-use assets, January 1, 2019 $ 1,570 - Additions to right-of-use assets 267 - Right-of-use assets, December 31, 2019 1,837 - Accumulated amortization (461 ) - Right-of use assets, NBV 1,376 -

Note 6 - Investments

Note 6 - Investments	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	6. Investments: Investments consisted of the following as of December 31, 2019 December 31, 2018: December 31, 2019 Cost Unrealized Market Guaranteed investment certificate(s) 12,008 18 12,026 Commercial notes 3,736 - 3,736 Canadian promissory note 1,996 - 1,996 17,740 18 17,758 December 31, 2018 Cost Unrealized Market Guaranteed investment certificate(s) 440 - 440

Note 7 - Fair Value Measurement

Note 7 - Fair Value Measurements and Financial Instruments	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	7. Fair value measurements and financial instruments: The fair value hierarchy establishes three Level 1 Level 2 not Level 3 no The fair value hierarchy gives the highest priority to Level 1 3 The following table presents the Company’s assets that are measured at fair value on a recurring basis for the periods presented: December 31, Level 1 Level 2 Level 3 Assets High interest savings account $ 2,989 $ - $ 2,989 - Commercial notes 6,235 - 6,235 - Canadian provincial promissory notes 5,493 - 5,493 - Guaranteed investment certificates, issued by a Canadian financial institution 81,243 - 81,243 - $ 95,960 $ - $ 95,960 $ - December 31, Level 1 Level 2 Level 3 Assets High interest savings account $ 496 $ - $ 496 $ - United States treasury bills 3,989 - 3,989 - Canadian provincial promissory notes 5,991 - 5,991 - Guaranteed investment certificates, Royal Bank of Canada 4,642 - 4,642 - $ 15,118 $ - $ 15,118 $ -

Note 8 - Accrued Liabilities

Note 8 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	8. Accrued liabilities: Accrued liabilities as of December 31, 2019 December 31, 2018 December 31, December 31, Accrued personnel related costs $ 1,739 $ 955 Accrued research and development expenses 1,062 257 Other accrued expenses 257 262 $ 3,058 $ 1,474

Note 9 - Lease Liability

Note 9 - Lease Liability	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	9. Lease liability Aptose leases office space and lab space in San Diego, California. The lease for the office space expires on March 31, 2023 5 February 29, 2019, February 18, 2019 February 28, 2022. June 30, 2023 5 not Minimum payments, undiscounted, under our operating leases are as follows: Years ending December 31, 2020 $ 534 2021 545 2022 463 2023 119 Thereafter - $ 1,661 To calculate the lease liability, the lease payments in the table above were discounted over the remaining term of the leases using the Company’s incremental borrowing rate as at January 1, 2019 842, Year ended Weighted-average remaining term – operating leases (years) 3.3 Weighted-average discount rate – operating leases 5.43 % Lease liability, current portion 521 Lease liability, long term portion 1,011 Lease liability, total 1,532 Right-of-use assets obtained in exchange for new operating lease liabilities are as follows: Year ended Right-of-use assets recorded upon adoption of Topic 842, January 1, 2019 $ 1,570 Right-of-use assets obtained in exchange for new operating lease liabilities in the period $ 267 Operating lease costs and operating cash flows from our operating leases are as follows: Year ended Operating lease cost $ 551 Operating cash flows from operating leases $ 471 Comparable figures are not

Note 10 - Share Capital

Note 10 - Share Capital	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10. Share capital: The Company has authorized share capital of an unlimited number of common voting shares. (a) Equity issuances: (i) December 2019 On December 19, 2019, 18,543,750 $4.00 $74.175 $68.588 7% (ii) June 2019 On June 3, 2019, 11,500,000 $1.85 $21.275 $19.594 7% (iii) 2019 On May 7, 2019, 2019 $20 30 May 13, 2019, 171,428 2019 $360 May 7, 2019 December 16, 2019, 2019 1,800,000 $2.43 $4.37 (iv) 2018 On May 30, 2018, 2018 $20 30 June 8, 2018, 170,261 2018 $600 January 1, 2019 May 24, 2019, 2018 5,502,433 $1.82 $10 May 24, 2019, $11.9 2018 May 24, 2019, 6,409,980, (v) 2017 On October 27, 2017, 2017 $15,500,000 30 December 31, 2017, 357,143 $500 $324 321,429 December 31, 2018, 5,231,953 $2.87 $15 December 31, 2018, $15.5 (vi) 2019 On May 24, 2019, may, $40 May 24, 2019 December 16, 2019, not (vii) 2018 On March 27, 2018, may, $30 December 31, 2018, 4,085,615 $2.71 $11 $10.7 January 1, 2019 May 24, 2019, 77,349 $2.37 $183 $178 3% May 24, 2019, $11.2 $10.9 (b) Loss per share: Loss per common share is calculated using the weighted average number of common shares outstanding and is presented in the table below: (in thousands) Year ended Year ended Net loss $ (26,277 ) $ (28,868 ) Weighted-average common shares – basic and diluted 50,160 33,391 Net loss per share – basic and diluted $ (0.52 ) $ (0.86 ) The effect of any potential exercise of the Company’s stock options outstanding during the year has been excluded from the calculation of diluted loss per common share as it would be anti-dilutive.

Note 11 - Stock-based Compensat

Note 11 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	11. Stock-based compensation: (a) Stock options Under the Company’s stock option plan, options, rights and other entitlements may 17.5% 13.3 December 31, 2019. four 10 Stock option transactions for the years ended December 31, 2018 2019 Option numbers are in (000’s) Options Year ended Weighted Aggregate Outstanding, December 31, 2017 2,344 $ 3.46 Granted 2,320 2.98 Exercised (114 ) 2.04 Expired (51 ) 2.34 Forfeited (10 ) 4.97 Outstanding, December 31, 2018 4,489 $ 3.11 Granted 2,160 2.00 Exercised (312 ) 2.32 Expired (67 ) 4.61 Forfeited (329 ) 2.36 Outstanding, December 31, 2019 5,941 2.84 7.6 16,866,623 Exercisable, December 31, 2019 3,057 3.44 6.5 6,853,978 Vested and expected to vest, December 31, 2109 5,508 2.89 7.5 15,364,726 Aggregate intrinsic value represents the excess of the value of the closing stock price on the previous trading day of the respective balance sheet dates over the exercise price of the stock options. Total intrinsic value of options exercised was $259 2019 2018 $255 As of December 31, 2019, $1.38 1.77 The following table presents the weighted average assumptions that were used in the Black-Scholes option pricing model to determine the fair value of stock options granted during the year, and the resultant weighted average fair values: Year ended Year ended Risk-free interest rate 2.18 % 2.43 % Expected dividend yield - - Expected volatility 83.9 % 93.3 % Expected life of options (years) 5 5 Grant date fair value $ 1.34 $ 2.22 The Company uses historical data to estimate the expected dividend yield and expected volatility of its common shares in determining the fair value of stock options. The expected life of the options represents the estimated length of time the options are expected to remain outstanding. Stock options granted by the Company during the year ended December 31, 2019, 50% one 16.67% three 160,000 50% one 25% two 335,000 100% one Stock options granted by the Company during the year ended December 30, 2018 50% one 16.67% three 166,000 50% one 25% two 850,000 (b) Restricted share units The Company has a stock incentive plan (SIP) pursuant to which the Board may one December 31, 2019 2018 Year ended, Year ended, Number Weighted Number Weighted Outstanding, December 31. 2018 - $ - - $ - Granted 80 2.00 150 3.35 Redeemed (40 ) 2.00 (150 ) 3.35 Outstanding, December 31, 2019 40 $ 2.00 - $ - On June 3, 2019, 80,000 40,000 three one September 3, 2019, 50% 40,000 On July 13, 2018, 150,000 three The grant date fair value of the June 3, 2019 July 13, 2018 (c) Share-based payment expense The Company recorded share-based payment expense related to stock options and RSUs as follows: Year ended Year ended Research and development $ 474 $ 1,026 General and administrative 1,822 3,250 Total $ 2,296 $ 4,276

Note 12 - Related Party Transac

Note 12 - Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	12. Related party transactions: The Company uses Moores Cancer Center at the University of California San Diego (UCSD) to provide pharmacology lab services to the Company. Dr. Stephen Howell is the Acting Chief Medical Officer of Aptose and is also a Professor of Medicine at UCSD and oversees the laboratory work. The work is completed under the terms of research services agreements executed in March 2015 March 2019, twelve $300,000. During the year ended December 31, 2019, $223 2018 $279

Note 13 - Collaborative Agreeme

Note 13 - Collaborative Agreements	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Collaborative Agreements [Text Block]	13. Collaborative agreements: The Company enters into research, development and license agreements in the ordinary course of business where the Company receives research services and rights to proprietary technologies. Milestone and royalty payments that may Under the Company’s license agreement with CrystalGenomics for rights to CG- 806, $16 2 $44 may not On June 13, 2018, 806 $6 2 $20 may not On March 7, 2018, 581, two $125

Note 14 - Income Taxes

Note 14 - Income Taxes	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	14. Income taxes: (a) Recent tax legislation In December 2017 January 1, 2018, 35% 21%, 2017 2018, (b) Income taxes For the years ended December 31, 2018 2019, December 31, 2019 December 31, 2018 Loss attributed to US foreign operations $ (20,470 ) $ (21,807 ) Loss attributed to Canadian operations (5,807 ) (7,061 ) Income (loss) before income taxes (26,277 ) (28,868 ) (c) Tax rate reconciliation Major items causing the Company’s income tax rate to differ from the statutory rate of approximately 26.5% December 31, 2018 26.5% Year ended Year ended Net loss $ (26,277 ) $ (28,868 ) Statutory Canadian corporate tax rate 26.5 % 26.5 % Computed expected tax recovery $ (6,963 ) $ (7,650 ) Non-deductible permanent differences (1,305 ) 1,422 Change in valuation allowance 12,146 4,528 Foreign tax rate differential (286 ) (325 ) Foreign exchange differences - 2,183 Prior year true-up adjustments (3,563 ) - Other (29 ) (158 ) $ - $ - (d) Significant components of deferred taxes The tax effects of temporary differences that give rise to significant portions of the unrecognized deferred tax assets are presented below: December 31, 2019 December 31, 2018 Net operating losses carried forward $ 26,786 $ 19,567 Research and development expenditures 5,031 5,024 Property, equipment, and other intangible assets 4,191 4,161 Research and development tax credits 3,685 394 Financing costs 2,010 452 Right-of-use assets 41 - Total deferred tax assets 41,744 29,598 Valuation allowance (41,744 ) (29,598 ) Net deferred tax asset $ - $ - The valuation allowance at December 31, 2019 not not not not not not The Company has undeducted research and development expenditures, totaling $18.958 $4.113 2020, $0.557 2038. In addition, the Company has Canadian non-capital loss carryforwards of $97.127 not 2026. $0.586 not 2034. The Company files income tax returns with Canada and its provinces and territories. Generally we are subject to routine examinations by the Canada Revenue Agency ("CRA"). Income tax returns filed with various provincial jurisdictions are generally open to examination for periods of four five The Company also files income tax returns for our U.S. operations and subsidiary with the U.S. federal and state tax jurisdictions. Generally, we are subject to routine examination by taxing authorities in the U.S. jurisdictions. There are presently no

Note 15 - Selected Quarterly Fi

Note 15 - Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Quarterly Financial Information [Text Block]	15. Selected quarterly financial data (unaudited): Selected financial data (unaudited) for the periods presented was as follows: March 31, June 30, September 30, December 31, Revenue $ - $ - $ - $ - Net loss (5,506 ) (6,218 ) (6,844 ) (7,709 ) Basic and diluted loss per common share (0.14 ) (0.13 ) (0.12 ) (0.13 ) March 31, June 30, September 30, December 31, Revenue $ - $ - $ - $ - Net loss (6,814 ) (10,262 ) (5,531 ) (6,261 ) Basic and diluted loss per common share (0.23 ) (0.30 ) (0.16 ) (0.17 )

Note 16 - Subsequent Events

Note 16 - Subsequent Events	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	16. Subsequent events (a) Subsequent to the year end, the Company issued 5,808,834 $6.82. 50% one 16.67% three 861,834 50% one 25% two (b) Subsequent to the year end, the Company issued 161,775 $2.68.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	(a) Basis of consolidation: These consolidated financial statements include the accounts of its subsidiaries. All intercompany transactions, balances, revenue and expenses are eliminated on consolidation.
Basis of Accounting, Policy [Policy Text Block]	(b) Basis of presentation: These consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States, or GAAP and the rules and regulations of the Securities and Exchange Commission, or SEC, related to annual reports filed on Form 10
Use of Estimates, Policy [Policy Text Block]	(c) Significant accounting policies, estimates and judgments: The preparation of the consolidated financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of revenue and expenses during the reporting period. Actual outcomes could differ from those estimates. The consolidated financial statements include estimates, which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements and may The estimates and underlying assumptions are reviewed on a regular basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected.
Lessee, Leases [Policy Text Block]	(d) Leases Effective January 1, 2019, No. 2016 02, 842 twelve Impact of adoption: As a result of adopting Topic 842, January 1, 2019, $1.570 $1.647 $78
Cash and Cash Equivalents, Policy [Policy Text Block]	(e) Cash and cash equivalents: Cash and cash equivalents are short-term highly liquid investments with original maturities of 90
Investment, Policy [Policy Text Block]	(f) Investments: Investments consist of time deposits with original maturities greater than 90
Concentration Risk, Credit Risk, Policy [Policy Text Block]	(g) Concentration of risk: The Company is subject to credit risk from the Company’s cash and cash equivalents and investments. The carrying amount of the financial assets represents the maximum credit exposure. The Company manages credit risk associated with its cash and cash equivalents and investments by maintaining minimum standards of R1
Property, Plant and Equipment, Policy [Policy Text Block]	(h) Property and equipment: Property and equipment is measured at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset. The Company records depreciation at rates that charge operations with the cost of the assets over their estimated useful lives on a straight-line basis as follows: Office furniture (years) 5 Laboratory equipment (years) 5 Computer hardware (years) 3 Computer software (years) 3 Leasehold improvements Life of lease The residual value, useful life and methods of depreciation of the assets are reviewed at each reporting period and adjusted prospectively if appropriate.
Research and Development Expense, Policy [Policy Text Block]	(i) Research and development: Research and development (R&D) costs are expensed as incurred. R&D costs consist primarily of salaries and benefits, stock-based compensation, manufacturing, contract services, clinical trials, intangibles, and research related overhead. Non-refundable advance payments for goods and services that will be used in future research are recorded in prepaid and other assets and are expensed when the services are performed.
Fair Value Measurement, Policy [Policy Text Block]	(j) Fair value: The Company measures its financial assets and liabilities at fair value. The carrying amounts for the Company’s financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
Share-based Payment Arrangement [Policy Text Block]	(k) Stock-based compensation: The Company has a stock-based compensation plan (the “Plan”) available to officers, directors, employees and consultants with grants under the Plan approved by the Company’s Board of Directors. Under the Plan, the exercise price of each option equals the closing trading price of the Company’s stock on the day prior to the grant if the grant is made during the trading day or the closing trading price on the day of grant if the grant is issued after markets have closed. Vesting is provided for at the discretion of the Board of Directors and the expiration of options is to be no 10 The Company uses the fair value based method of accounting for employee awards granted under the Plan. The Company calculates the fair value of each stock option grant using the Black-Scholes option pricing model at the grant date. The stock-based compensation cost of the options is recognized as stock-based compensation expense over the relevant vesting period of the stock options using an estimate of the number of options that will eventually vest. Stock options awarded to non-employees are accounted for at the fair value of the goods received or the services rendered. The fair value is measured at the grant date. In June 2018, No 2018 07, 718 December 15, 2018. not The Company has a stock incentive plan pursuant to which the Board may
Segment Reporting, Policy [Policy Text Block]	(l) Segment reporting: Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, or CODM. The Company’s Chief Executive Officer serves as its CODM. The Company views its operations and manages its business as one
Earnings Per Share, Policy [Policy Text Block]	(m) Loss per share: Basic loss per share is computed by dividing the net loss available to common shareholders by the weighted average number of shares outstanding during the year. Diluted loss per share is computed similarly to basic loss per share except that the weighted average share outstanding is increased to include additional shares for the assumed exercise of stock options and warrants, if dilutive. The number of additional shares is calculated by assuming that outstanding stock options and warrants were exercised and that the proceeds from such exercises were used to acquire common stock at the average market price during the year. The inclusion of the Company’s stock options and warrants in the computation of diluted loss per share has an anti-dilutive effect on the loss per share and, therefore, they have been excluded from the calculation of diluted loss per share.
Income Tax, Policy [Policy Text Block]	(n) Income taxes: The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which these temporary differences are expected to be recovered or settled. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not not The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. Reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filing is more likely than not December 31, 2019 December 31, 2018, not not

Note 2 - Significant Accounti_2

Note 2 - Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Property, Plant and Equipment, Useful Life [Table Text Block]	Office furniture (years) 5 Laboratory equipment (years) 5 Computer hardware (years) 3 Computer software (years) 3 Leasehold improvements Life of lease

Note 4 - Property and Equipme_2

Note 4 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, 2019 Cost Accumulated Net book value Laboratory equipment $ 185 $ 160 $ 25 Computer hardware 122 60 62 Computer software 222 128 94 Office furniture 116 51 65 Leasehold improvements 177 89 88 $ 822 $ 488 $ 334 December 31, 2018 Cost Accumulated Net book value Laboratory equipment $ 176 $ 129 $ 47 Computer hardware 80 40 40 Computer software 222 80 142 Office furniture 82 28 54 Leasehold improvements 160 59 101 $ 720 $ 336 $ 384

Note 5 - Right of-use Assets,_2

Note 5 - Right of-use Assets, Operating Leases (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Right-of-use Assets [Table Text Block]	Year ended Year ended Right-of-use assets, January 1, 2019 $ 1,570 - Additions to right-of-use assets 267 - Right-of-use assets, December 31, 2019 1,837 - Accumulated amortization (461 ) - Right-of use assets, NBV 1,376 -

Note 6 - Investments (Tables)

Note 6 - Investments (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Investment [Table Text Block]	December 31, 2019 Cost Unrealized Market Guaranteed investment certificate(s) 12,008 18 12,026 Commercial notes 3,736 - 3,736 Canadian promissory note 1,996 - 1,996 17,740 18 17,758 December 31, 2018 Cost Unrealized Market Guaranteed investment certificate(s) 440 - 440

Note 7 - Fair Value Measureme_2

Note 7 - Fair Value Measurements and Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	December 31, Level 1 Level 2 Level 3 Assets High interest savings account $ 2,989 $ - $ 2,989 - Commercial notes 6,235 - 6,235 - Canadian provincial promissory notes 5,493 - 5,493 - Guaranteed investment certificates, issued by a Canadian financial institution 81,243 - 81,243 - $ 95,960 $ - $ 95,960 $ - December 31, Level 1 Level 2 Level 3 Assets High interest savings account $ 496 $ - $ 496 $ - United States treasury bills 3,989 - 3,989 - Canadian provincial promissory notes 5,991 - 5,991 - Guaranteed investment certificates, Royal Bank of Canada 4,642 - 4,642 - $ 15,118 $ - $ 15,118 $ -

Note 8 - Accrued Liabilities (T

Note 8 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, December 31, Accrued personnel related costs $ 1,739 $ 955 Accrued research and development expenses 1,062 257 Other accrued expenses 257 262 $ 3,058 $ 1,474

Note 9 - Lease Liability (Table

Note 9 - Lease Liability (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Years ending December 31, 2020 $ 534 2021 545 2022 463 2023 119 Thereafter - $ 1,661
Lessee, Operating Lease Liability and Weighted Average [Table Text Block]	Year ended Weighted-average remaining term – operating leases (years) 3.3 Weighted-average discount rate – operating leases 5.43 % Lease liability, current portion 521 Lease liability, long term portion 1,011 Lease liability, total 1,532
Schedule of Right-of-use Asset Obtained in Exchange For Operating Lease Liability [Table Text Block]	Year ended Right-of-use assets recorded upon adoption of Topic 842, January 1, 2019 $ 1,570 Right-of-use assets obtained in exchange for new operating lease liabilities in the period $ 267
Lease, Cost [Table Text Block]	Year ended Operating lease cost $ 551 Operating cash flows from operating leases $ 471

Note 10 - Share Capital (Tables

Note 10 - Share Capital (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	(in thousands) Year ended Year ended Net loss $ (26,277 ) $ (28,868 ) Weighted-average common shares – basic and diluted 50,160 33,391 Net loss per share – basic and diluted $ (0.52 ) $ (0.86 )

Note 11 - Stock-based Compens_2

Note 11 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Option numbers are in (000’s) Options Year ended Weighted Aggregate Outstanding, December 31, 2017 2,344 $ 3.46 Granted 2,320 2.98 Exercised (114 ) 2.04 Expired (51 ) 2.34 Forfeited (10 ) 4.97 Outstanding, December 31, 2018 4,489 $ 3.11 Granted 2,160 2.00 Exercised (312 ) 2.32 Expired (67 ) 4.61 Forfeited (329 ) 2.36 Outstanding, December 31, 2019 5,941 2.84 7.6 16,866,623 Exercisable, December 31, 2019 3,057 3.44 6.5 6,853,978 Vested and expected to vest, December 31, 2109 5,508 2.89 7.5 15,364,726
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year ended Year ended Risk-free interest rate 2.18 % 2.43 % Expected dividend yield - - Expected volatility 83.9 % 93.3 % Expected life of options (years) 5 5 Grant date fair value $ 1.34 $ 2.22
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Year ended, Year ended, Number Weighted Number Weighted Outstanding, December 31. 2018 - $ - - $ - Granted 80 2.00 150 3.35 Redeemed (40 ) 2.00 (150 ) 3.35 Outstanding, December 31, 2019 40 $ 2.00 - $ -
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Year ended Year ended Research and development $ 474 $ 1,026 General and administrative 1,822 3,250 Total $ 2,296 $ 4,276

Note 14 - Income Taxes (Tables)

Note 14 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	December 31, 2019 December 31, 2018 Loss attributed to US foreign operations $ (20,470 ) $ (21,807 ) Loss attributed to Canadian operations (5,807 ) (7,061 ) Income (loss) before income taxes (26,277 ) (28,868 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year ended Year ended Net loss $ (26,277 ) $ (28,868 ) Statutory Canadian corporate tax rate 26.5 % 26.5 % Computed expected tax recovery $ (6,963 ) $ (7,650 ) Non-deductible permanent differences (1,305 ) 1,422 Change in valuation allowance 12,146 4,528 Foreign tax rate differential (286 ) (325 ) Foreign exchange differences - 2,183 Prior year true-up adjustments (3,563 ) - Other (29 ) (158 ) $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2019 December 31, 2018 Net operating losses carried forward $ 26,786 $ 19,567 Research and development expenditures 5,031 5,024 Property, equipment, and other intangible assets 4,191 4,161 Research and development tax credits 3,685 394 Financing costs 2,010 452 Right-of-use assets 41 - Total deferred tax assets 41,744 29,598 Valuation allowance (41,744 ) (29,598 ) Net deferred tax asset $ - $ -

Note 15 - Selected Quarterly _2

Note 15 - Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Quarterly Financial Information [Table Text Block]	March 31, June 30, September 30, December 31, Revenue $ - $ - $ - $ - Net loss (5,506 ) (6,218 ) (6,844 ) (7,709 ) Basic and diluted loss per common share (0.14 ) (0.13 ) (0.12 ) (0.13 ) March 31, June 30, September 30, December 31, Revenue $ - $ - $ - $ - Net loss (6,814 ) (10,262 ) (5,531 ) (6,261 ) Basic and diluted loss per common share (0.23 ) (0.30 ) (0.16 ) (0.17 )

Note 1 - Reporting Entity (Deta

Note 1 - Reporting Entity (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)shares
Stock Issued During Period, Shares, New Issues | shares	30,043,750
Proceeds from Issuance of Common Stock, Gross	$ 95,450
Proceeds from Issuance of Common Stock, Net of Share Issuance Costs	$ 88,180
Aspire [Member]
Stock Issued During Period, Shares, New Issues | shares	7,302,433
Proceeds from Issuance of Common Stock, Gross	$ 14,400
Proceeds from Issuance of Common Stock, Net of Share Issuance Costs	$ 14,400

Note 2 - Significant Accounti_3

Note 2 - Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018	Jan. 01, 2018
Operating Lease, Right-of-Use Asset	$ 1,376	$ 1,570
Operating Lease, Liability, Total	$ 1,532	1,647
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Accounting Standards Update 2016-02 [Member]
Landlord Inducements		$ (78)

Note 2 - Significant Accounti_4

Note 2 - Significant Accounting Policies - Property, Plant and Equipment Useful Life (Details)	12 Months Ended
	Dec. 31, 2019
Furniture and Fixtures [Member]
Property, plant and equipment, useful life (Year)	5 years
Laboratory Equipment [Member]
Property, plant and equipment, useful life (Year)	5 years
Computer Equipment [Member]
Property, plant and equipment, useful life (Year)	3 years
Software and Software Development Costs [Member]
Property, plant and equipment, useful life (Year)	3 years
Leasehold Improvements [Member]
Property, plant and equipment, estimated useful life	Life of lease

Note 3 - Cash and Cash Equiva_2

Note 3 - Cash and Cash Equivalents (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Cash, Ending Balance	$ 1,640	$ 621
Cash Equivalents, at Carrying Value, Total	$ 78,202	$ 14,678

Note 4 - Property and Equipme_3

Note 4 - Property and Equipment - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Property, plant and equipment, gross	$ 822	$ 720
Accumulated depreciation	488	336
Property, plant and equipment, net	334	384
Laboratory Equipment [Member]
Property, plant and equipment, gross	185	176
Accumulated depreciation	160	129
Property, plant and equipment, net	25	47
Computer Equipment [Member]
Property, plant and equipment, gross	122	80
Accumulated depreciation	60	40
Property, plant and equipment, net	62	40
Software and Software Development Costs [Member]
Property, plant and equipment, gross	222	222
Accumulated depreciation	128	80
Property, plant and equipment, net	94	142
Furniture and Fixtures [Member]
Property, plant and equipment, gross	116	82
Accumulated depreciation	51	28
Property, plant and equipment, net	65	54
Leasehold Improvements [Member]
Property, plant and equipment, gross	177	160
Accumulated depreciation	89	59
Property, plant and equipment, net	$ 88	$ 101

Note 5 - Right of-use Assets,_3

Note 5 - Right of-use Assets, Operating Leases - Schedule of Right-of-use Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jan. 01, 2019	Jan. 01, 2018
Right-of-use assets, operating leases	$ 1,376		$ 1,570
Additions to right-of-use assets	267
Right-of-use assets before Accumulated amortization	1,837
Accumulated amortization	(461)
Right-of use assets	$ 1,376		$ 1,570

Note 6 - Investments - Investme

Note 6 - Investments - Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Investment, Cost	$ 17,740
Investment, Unrealized gain/(loss)	18
Investment, Market value	17,758
Investments [Member]
Investment, Cost	12,008	$ 440
Investment, Unrealized gain/(loss)	18
Investment, Market value	12,026	$ 440
Corporate Debt Securities [Member]
Investment, Cost	3,736
Investment, Unrealized gain/(loss)
Investment, Market value	3,736
Canadian Provincial Promissory Notes [Member]
Investment, Cost	1,996
Investment, Unrealized gain/(loss)
Investment, Market value	$ 1,996

Note 7 - Fair Value Measureme_3

Note 7 - Fair Value Measurements and Financial Instruments - Assets Measured on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Assets, fair value	$ 95,960	$ 15,118
Fair Value, Inputs, Level 1 [Member]
Assets, fair value
Fair Value, Inputs, Level 2 [Member]
Assets, fair value	95,960	15,118
Fair Value, Inputs, Level 3 [Member]
Assets, fair value
Bank Time Deposits [Member]
Assets, fair value	2,989	496
Bank Time Deposits [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value
Bank Time Deposits [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	2,989	496
Bank Time Deposits [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value
Corporate Debt Securities [Member]
Assets, fair value	6,235
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	6,235
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value
US Treasury Securities [Member]
Assets, fair value		3,989
US Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value
US Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value		3,989
US Treasury Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value
Canadian Provincial Promissory Notes [Member]
Assets, fair value	5,493	5,991
Canadian Provincial Promissory Notes [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value
Canadian Provincial Promissory Notes [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	5,493	5,991
Canadian Provincial Promissory Notes [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value
Investments [Member]
Assets, fair value	81,243	4,642
Investments [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value
Investments [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	81,243	4,642
Investments [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value

Note 8 - Accrued Liabilities -

Note 8 - Accrued Liabilities - Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accrued personnel related costs	$ 1,739	$ 955
Accrued research and development expenses	1,062	257
Other accrued expenses	257	262
	$ 3,058	$ 1,474

Note 9 - Lease Liability (Detai

Note 9 - Lease Liability (Details Textual)	Dec. 31, 2019
Lessee, Operating Lease, Renewal Term	5 years

Note 9 - Lease Liability - Sche

Note 9 - Lease Liability - Schedule of Minimum Payments Under Operating Leases (Details) $ in Thousands	Dec. 31, 2019USD ($)
2020	$ 534
2021	545
2022	463
2023	119
Thereafter
	$ 1,661

Note 9 - Lease Liability - Leas

Note 9 - Lease Liability - Lease Liability (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Weighted-average remaining term – operating leases (Year)	3 years 109 days
Weighted-average discount rate – operating leases	5.43%
Lease liability, current portion	$ 521
Lease liability, long term portion	1,011
Operating Lease, Liability, Total	$ 1,532	$ 1,647

Note 9 - Lease Liability - Sc_2

Note 9 - Lease Liability - Schedule of Right-of-use Asset Obtained in Exchange for Operating Lease Liability (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jan. 01, 2019	Jan. 01, 2018
Operating Lease, Right-of-Use Asset	$ 1,376		$ 1,570
Right-of-use assets obtained in exchange for new operating lease liabilities in the period	$ 267

Note 9 - Lease Liability - Oper

Note 9 - Lease Liability - Operating Lease Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating lease cost	$ 551
Operating cash flows from operating leases	$ 471

Note 10 - Share Capital (Detail

Note 10 - Share Capital (Details Textual) - USD ($)	Dec. 19, 2019	Jun. 03, 2019	May 24, 2019	May 13, 2019	Jun. 08, 2018	May 24, 2019	Dec. 16, 2019	Dec. 31, 2019	May 24, 2019	Dec. 31, 2018	Dec. 31, 2017	May 24, 2019	Dec. 31, 2019	May 07, 2019	May 30, 2018	Mar. 27, 2018	Oct. 27, 2017
Stock Issued During Period, Shares, New Issues								30,043,750
Proceeds from Issuance of Common Stock, Gross								$ 95,450,000
Proceeds from Issuance of Common Stock, Net of Share Issuance Costs								88,180,000
December 2019 Public Offering [Member]
Stock Issued During Period, Shares, New Issues	18,543,750
Shares Issued, Price Per Share	$ 4
Proceeds from Issuance of Common Stock, Gross	$ 74,175,000
Proceeds from Issuance of Common Stock, Net of Share Issuance Costs	$ 68,588,000
Stock Issuance, Percent of Cash Commission to Broker	7.00%
Stock Issued During Period, Value, New Issues								68,588,000
Proceeds from Issuance of Common Stock								68,883,000
June 2019 Public Offering [Member]
Stock Issued During Period, Shares, New Issues		11,500,000
Shares Issued, Price Per Share		$ 1.85
Proceeds from Issuance of Common Stock, Gross		$ 21,275,000
Proceeds from Issuance of Common Stock, Net of Share Issuance Costs		$ 19,594,000
Stock Issuance, Percent of Cash Commission to Broker		7.00%
Stock Issued During Period, Value, New Issues								19,594,000
Proceeds from Issuance of Common Stock								19,736,000
The 2019 Share Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues				171,428			1,800,000
Shares Issued, Price Per Share							$ 2.43
Proceeds from Issuance of Common Stock, Gross							$ 4,370,000
Stock Issuance Program, Authorized Amount														$ 20,000,000
Stock Issued During Period, Value, New Issues				$ 360,000				4,730,000
Proceeds from Issuance of Common Stock							$ 4,370,000	4,370,000
The 2018 Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues					170,261	5,502,433			6,409,980
Shares Issued, Price Per Share			$ 1.82			$ 1.82			$ 1.82			$ 1.82
Proceeds from Issuance of Common Stock, Gross						$ 10,000,000			$ 11,900,000
Stock Issuance Program, Authorized Amount															$ 20,000,000
Stock Issued During Period, Value, New Issues					$ 600,000			10,000,000		2,526,000
Proceeds from Issuance of Common Stock						10,000,000		10,000,000	11,900,000	$ 1,926,000
The 2017 Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues										5,231,953	357,143
Shares Issued, Price Per Share										$ 2.87
Proceeds from Issuance of Common Stock, Gross										$ 15,000,000
Stock Issuance Program, Authorized Amount																	$ 15,500,000
Stock Issued During Period, Value, New Issues										14,995,000
Proceeds from Issuance of Common Stock										15,000,000
Proceeds from Issuance of Private Placement, Gross											$ 500,000
Proceeds from Issuance of Private Placement										$ 15,000,000	$ 324,000		$ 15,500,000
Stock Issued During Period, Shares, Issued for Services											321,429
The 2019 ATM Offering [Member]
Stock Issued During Period, Shares, New Issues			0
Stock Issuance Program, Authorized Amount			$ 40,000,000			$ 40,000,000			$ 40,000,000			$ 40,000,000
The 2018 ATM Offering [Member]
Stock Issued During Period, Shares, New Issues						77,349				4,085,615
Shares Issued, Price Per Share			$ 2.37			$ 2.37			$ 2.37	$ 2.71		$ 2.37
Proceeds from Issuance of Common Stock, Gross						$ 183,000				$ 11,000,000		$ 11,200,000
Stock Issuance, Percent of Cash Commission to Broker			3.00%			3.00%			3.00%			3.00%
Stock Issuance Program, Authorized Amount																$ 30,000,000
Stock Issued During Period, Value, New Issues								178,000		10,710,000
Proceeds from Issuance of Common Stock						$ 178,000		$ 178,000		$ 10,720,000		$ 10,900,000

Note 10 - Share Capital - Loss

Note 10 - Share Capital - Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Net loss	$ (7,709)	$ (6,844)	$ (6,218)	$ (5,506)	$ (6,261)	$ (5,531)	$ (10,262)	$ (6,814)	$ (26,277)	$ (28,868)
Weighted-average common shares – basic and diluted (in shares)									50,160	33,391
Net loss per share – basic and diluted (in dollars per share)	$ (0.13)	$ (0.12)	$ (0.13)	$ (0.14)	$ (0.17)	$ (0.16)	$ (0.30)	$ (0.23)	$ (0.52)	$ (0.86)

Note 11 - Stock-based Compens_3

Note 11 - Stock-based Compensation (Details Textual) - USD ($) $ in Thousands	Sep. 03, 2019	Jun. 03, 2019	Jul. 13, 2018	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Subscription Rate				17.50%
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares				13,300,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value				$ 259	$ 255
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount				$ 1,380
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition				1 year 281 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				2,160,000	2,320,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				80,000	150,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period				40,000	150,000
Employee Stock Option Vesting Schedule I [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				160,000	166,000
Employee Stock Option Vesting Schedule II [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				100.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				335,000	850,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			90 days
Stock Redemption, Shares Per Share				1
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		80,000	150,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	40,000
Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				50.00%
Share-based Payment Arrangement, Tranche One [Member] | Employee Stock Option Vesting Schedule I [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				50.00%	50.00%
Share-based Payment Arrangement, Tranche One [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		90 days
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		40,000
Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				16.67%	16.67%
Share-based Payment Arrangement, Tranche Two [Member] | Employee Stock Option Vesting Schedule I [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				25.00%	25.00%
Share-based Payment Arrangement, Tranche Two [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		1 year
Share-based Payment Arrangement, Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				16.67%	16.67%
Share-based Payment Arrangement, Tranche Three [Member] | Employee Stock Option Vesting Schedule I [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				25.00%	25.00%
Share-based Compensation Award, Tranche Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				16.67%	16.67%

Note 11 - Stock-based Compens_4

Note 11 - Stock-based Compensation - Stock Option Transactions (Details) - USD ($) $ / shares in Units, shares in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Outstanding (in shares)	4,489	2,344
Outstanding, weighted average exercise price (in dollars per share)	$ 3.11	$ 3.46
Granted (in shares)	2,160	2,320
Granted, weighted average exercise price (in dollars per share)	$ 2	$ 2.98
Exercised (in shares)	(312)	(114)
Exercised, weighted average exercise price (in dollars per share)	$ 2.32	$ 2.04
Expired (in shares)	(67)	(51)
Expired, weighted average exercise price (in dollars per share)	$ 4.61	$ 2.34
Forfeited (in shares)	(329)	(10)
Forfeited, weighted average exercise price (in dollars per share)	$ 2.36	$ 4.97
Outstanding (in shares)	5,941	4,489
Outstanding, weighted average exercise price (in dollars per share)	$ 2.84	$ 3.11
Outstanding, weighted average remaining contractual life (Year)	7 years 219 days
Outstanding, aggregate intrinsic value	$ 16,866,623
Exercisable (in shares)	3,057
Exercisable, weighted average exercise price (in dollars per share)	$ 3.44
Exercisable, weighted average remaining contractual life (Year)	6 years 182 days
Exercisable, aggregate intrinsic value	$ 6,853,978
Vested and expected to vest (in shares)	5,508
Vested and expected to vest, weighted average exercise price (in dollars per share)	$ 2.89
Vested and expected to vest, weighted average remaining contractual life (Year)	7 years 182 days
Vested and expected to vest, aggregate intrinsic value	$ 15,364,726

Note 11 - Stock-based Compens_5

Note 11 - Stock-based Compensation - Weighted Average Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Risk-free interest rate	2.18%	2.43%
Expected dividend yield
Expected volatility	83.90%	93.30%
Expected life of options (Year)	5 years	5 years
Grant date fair value (in dollars per share)	$ 1.34	$ 2.22

Note 11 - Stock-based Compens_6

Note 11 - Stock-based Compensation - Restricted Stock Units (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Outstanding, balance (in shares)
Outstanding, weighted average grant date fair value (in dollars per share)	$ 2
Granted (in shares)	80	150
Granted, weighted average grant date fair value (in dollars per share)	$ 2	$ 3.35
Redeemed (in shares)	(40)	(150)
Redeemed, weighted average grant date fair value (in dollars per share)	$ 2	$ 3.35
Outstanding, balance (in shares)	40

Note 11 - Stock-based Compens_7

Note 11 - Stock-based Compensation - Share-based Payment Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based payment expense	$ 2,296	$ 4,276
Research and Development Expense [Member]
Share-based payment expense	474	1,026
General and Administrative Expense [Member]
Share-based payment expense	$ 1,822	$ 3,250

Note 12 - Related Party Trans_2

Note 12 - Related Party Transactions (Details Textual) - Moores Cancer Center at University of California San Diego [Member] - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2019
Extension for Services Agreement, Amount, Related Parties			$ 300,000
Research and Development Expense, Related Party [Member]
Related Party Transaction, Amounts of Transaction	$ 223,000	$ 279,000

Note 13 - Collaborative Agree_2

Note 13 - Collaborative Agreements (Details Textual) - USD ($) $ in Millions	Dec. 31, 2019	Jun. 13, 2018	Mar. 07, 2018
CrystalGenomics [Member]
Collaborative Agreement, Milestone Payment	$ 16
Collaborative Agreement, Regulatory Milestone	$ 44
CrystalGenomics [Member] | Exclusive License to CG806 in China, Development Milestones [Member]
Collaborative Agreement, Regulatory Milestone		$ 6
CrystalGenomics [Member] | Exclusive License to CG806 in China, Regulatory Milestones [Member]
Collaborative Agreement, Regulatory Milestone		$ 20
Ohm Oncology [Member]
Collaborative Agreements, Potential Additional Milestone Payments Receivable			$ 125

Note 14 - Income Taxes (Details

Note 14 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	26.50%	26.50%
Foreign Tax Authority [Member] | Canada Revenue Agency [Member]
Operating Loss Carryforwards, Total	$ 97,127
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total	586
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	18,958
Research Tax Credit Carryforward [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Tax Credit Carryforward, Amount	557
Investment Tax Credit Carryforward [Member] | Foreign Tax Authority [Member] | Canada Revenue Agency [Member]
Tax Credit Carryforward, Amount	$ 4,113

Note 14 - Income Taxes - Net Lo

Note 14 - Income Taxes - Net Loss (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Loss attributed to US foreign operations									$ (20,470)	$ (21,807)
Loss attributed to Canadian operations									(5,807)	(7,061)
Net loss	$ (7,709)	$ (6,844)	$ (6,218)	$ (5,506)	$ (6,261)	$ (5,531)	$ (10,262)	$ (6,814)	$ (26,277)	$ (28,868)

Note 14 - Income Taxes - Provis

Note 14 - Income Taxes - Provision for Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Net loss	$ (7,709)	$ (6,844)	$ (6,218)	$ (5,506)	$ (6,261)	$ (5,531)	$ (10,262)	$ (6,814)	$ (26,277)	$ (28,868)
Statutory Canadian corporate tax rate									26.50%	26.50%
Computed expected tax recovery									$ (6,963)	$ (7,650)
Non-deductible permanent differences									(1,305)	1,422
Change in valuation allowance									12,146	4,528
Foreign tax rate differential									(286)	(325)
Foreign exchange differences										2,183
Prior year true-up adjustments									(3,563)
Other									$ (29)	$ (158)

Note 14 - Income Taxes - Deferr

Note 14 - Income Taxes - Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Net operating losses carried forward	$ 26,786	$ 19,567
Research and development expenditures	5,031	5,024
Property, equipment, and other intangible assets	4,191	4,161
Research and development tax credits	3,685	394
Financing costs	2,010	452
Right-of-use assets	41
Total deferred tax assets	41,744	29,598
Valuation allowance	(41,744)	(29,598)
Net deferred tax asset

Note 15 - Selected Quarterly _3

Note 15 - Selected Quarterly Financial Data (Unaudited) - Quarterly Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Revenue
Net loss	$ (7,709)	$ (6,844)	$ (6,218)	$ (5,506)	$ (6,261)	$ (5,531)	$ (10,262)	$ (6,814)	$ (26,277)	$ (28,868)
Basic and diluted loss per common share (in dollars per share)	$ (0.13)	$ (0.12)	$ (0.13)	$ (0.14)	$ (0.17)	$ (0.16)	$ (0.30)	$ (0.23)	$ (0.52)	$ (0.86)

Note 16 - Subsequent Events (De

Note 16 - Subsequent Events (Details Textual) - $ / shares	Mar. 10, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		2,160,000	2,320,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 2	$ 2.98
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		312,000	114,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price		$ 2.32	$ 2.04
Employee Stock Option Vesting Schedule I [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		160,000	166,000
Employee Stock Option Vesting Schedule II [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		335,000	850,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		100.00%
Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		50.00%
Share-based Payment Arrangement, Tranche One [Member] | Employee Stock Option Vesting Schedule I [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		50.00%	50.00%
Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		16.67%	16.67%
Share-based Payment Arrangement, Tranche Two [Member] | Employee Stock Option Vesting Schedule I [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%	25.00%
Share-based Payment Arrangement, Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		16.67%	16.67%
Share-based Payment Arrangement, Tranche Three [Member] | Employee Stock Option Vesting Schedule I [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%	25.00%
Share-based Compensation Award, Tranche Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		16.67%	16.67%
Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	5,808,834
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 6.82
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	161,775
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$ 2.68
Subsequent Event [Member] | Employee Stock Option Vesting Schedule II [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	861,834
Subsequent Event [Member] | Share-based Payment Arrangement, Tranche One [Member] | Employee Stock Option Vesting Schedule I [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Subsequent Event [Member] | Share-based Payment Arrangement, Tranche One [Member] | Employee Stock Option Vesting Schedule II [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Subsequent Event [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Employee Stock Option Vesting Schedule I [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	16.67%
Subsequent Event [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Employee Stock Option Vesting Schedule II [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%
Subsequent Event [Member] | Share-based Payment Arrangement, Tranche Three [Member] | Employee Stock Option Vesting Schedule I [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	16.67%
Subsequent Event [Member] | Share-based Payment Arrangement, Tranche Three [Member] | Employee Stock Option Vesting Schedule II [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%
Subsequent Event [Member] | Share-based Compensation Award, Tranche Four [Member] | Employee Stock Option Vesting Schedule I [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	16.67%